Vangelis D. Karalis
Vangelis D. Karalis
Verified email at - Homepage
Cited by
Cited by
Bioavailability and bioequivalence: focus on physiological factors and variability
V Karalis, P Macheras, A Van Peer, VP Shah
Pharmaceutical research 25, 1956-1962, 2008
Bioequivalence of highly variable drugs: a comparison of the newly proposed regulatory approaches by FDA and EMA
V Karalis, M Symillides, P Macheras
Pharmaceutical research 29, 1066-1077, 2012
Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease
PC Robinson, R Terkeltaub, MH Pillinger, B Shah, V Karalis, E Karatza, ...
The American journal of medicine 135 (1), 32-38, 2022
Michaelis-Menten kinetics under spatially constrained conditions: application to mibefradil pharmacokinetics
K Kosmidis, V Karalis, P Argyrakis, P Macheras
Biophysical journal 87 (3), 1498-1506, 2004
Novel scaled average bioequivalence limits based on GMR and variability considerations
V Karalis, M Symillides, P Macheras
Pharmaceutical research 21, 1933-1942, 2004
Kinetics of anti-SARS-CoV-2 antibody responses 3 months post complete vaccination with BNT162b2; a prospective study in 283 health workers
E Terpos, IP Trougakos, V Karalis, I Ntanasis-Stathopoulos, S Gumeni, ...
Cells 10 (8), 1942, 2021
Geometric mean ratio-dependent scaled bioequivalence limits with leveling-off properties
V Karalis, P Macheras, M Symillides
European journal of pharmaceutical sciences 26 (1), 54-61, 2005
3D-Printed oral dosage forms: Mechanical properties, computational approaches and applications
D Karalia, A Siamidi, V Karalis, M Vlachou
Pharmaceutics 13 (9), 1401, 2021
Novel scaled bioequivalence limits with leveling-off properties
J Kytariolos, V Karalis, P Macheras, M Symillides
Pharmaceutical research 23, 2657-2664, 2006
Quantitative structure–pharmacokinetic relationships for disposition parameters of cephalosporins
V Karalis, A Tsantili-Kakoulidou, P Macheras
European journal of pharmaceutical sciences 20 (1), 115-123, 2003
Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations
V Karalis, P Macheras, M Bialer
CNS drugs 28, 69-77, 2014
Keeping a critical eye on the science and the regulation of oral drug absorption: a review
P Macheras, V Karalis, G Valsami
Journal of Pharmaceutical Sciences 102 (9), 3018-3036, 2013
A non-binary biopharmaceutical classification of drugs: the ABΓ system
P Macheras, V Karalis
International journal of pharmaceutics 464 (1-2), 85-90, 2014
High prevalence of anti-PF4 antibodies following ChAdOx1 nCov-19 (AZD1222) vaccination even in the absence of thrombotic events
E Terpos, M Politou, I Ntanasis-Stathopoulos, V Karalis, E Merkouri, ...
Vaccines 9 (7), 712, 2021
Drug disposition viewed in terms of the fractal volume of distribution
V Karalis, P Macheras
Pharmaceutical research 19, 697-704, 2002
On the leveling-off properties of the new bioequivalence limits for highly variable drugs of the EMA guideline
V Karalis, M Symillides, P Macheras
European journal of pharmaceutical sciences 44 (4), 497-505, 2011
Colchicine for the treatment of COVID-19 patients: efficacy, safety, and model informed dosage regimens
E Karatza, G Ismailos, V Karalis
Xenobiotica 51 (6), 643-656, 2021
Current regulatory approaches of bioequivalence testing
V Karalis, P Macheras
Expert opinion on drug metabolism & toxicology 8 (8), 929-942, 2012
From drug delivery systems to drug release, dissolution, IVIVC, BCS, BDDCS, bioequivalence and biowaivers
V Karalis, E Magklara, VP Shah, P Macheras
Pharmaceutical research 27, 2018-2029, 2010
The heterogeneous course of drug transit through the body
A Dokoumetzidis, V Karalis, A Iliadis, P Macheras
Trends in pharmacological sciences 25 (3), 140-146, 2004
The system can't perform the operation now. Try again later.
Articles 1–20